Oxford Gene Technology (OGT), the pioneer of microarray-based technologies, has introduced three new CytoSure ISCA aCGH arrays to meet all resolutions, multiplexing and budget requirements. Designed in collaboration with the International Standard Cytogenomic Array (ISCA) consortium, the 8 x 60k, 4 x 180k and 4 x 44k CytoSure ISCA formats, provide powerful arrays focusing on disease and syndrome-associated genome regions, in addition to offering whole genome coverage.
Using a proprietary 60-mer probe design and multiple rounds of optimisation, the CytoSure ISCA aCGH arrays ensure exceptional reliability and confident detection of genetic aberrations with high signal-to-noise ratios. These features have ensured that the CytoSure ISCA arrays are already used at a number of key facilities, including the Wessex Regional Genetics Laboratory, Salisbury UK where they were evaluated as part of an ongoing multi-platform aCGH comparison being carried out by the National Genetics Reference Laboratory (Wessex).
Each CytoSure array is accompanied with the user-centric CytoSure Interpret analysis software. This powerful and easy-to-use tool ensures effortless translation of data into meaningful results. Intuitive features include the “Accelerate” work flow, for customisable automation of routine data analysis, and full integration with existing data and publicly available cytogenetics databases including the Database of Genomic Variants (DGV, Canada) and DECIPHER (Sanger Institute, UK). “OGT has a strong and ongoing commitment to providing cytogeneticists with exceptional tools for accurate and reliable aberration detection” said James Clough, OGT’s Vice President Clinical and Genomic Solutions, “The development of our CytoSure ISCA arrays, in combination with our advanced CytoSure Interpret analysis software, is a clear example of this. We are delighted by the level of interest our CytoSure ISCA arrays are generating within the ISCA consortium around the world”.